Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translation

6 Oct 2022

Abstract excerpt

DNA damage response inhibitors are widely used anti-cancer agents that have potent activity against tumor cells with deficiencies in various DNA damage response proteins such as BRCA1/2. Inhibition of other proteins in this pathway including PARP, DNA-PK, WEE1, CHK1/2, ATR, or ATM can sensitize cancer cells to radiotherapy and chemotherapy, and such combinations are currently being tested in clinical trials for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Immune Cell Function and Interaction
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36276148
DOI: 10.3389/fonc.2022.998388

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-cancer immune responses to DNA damage response inhibitors: Molecular mechanisms and progress toward clinical translationPMID 36276148Read ↗

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical ApplicationsSemantic proximity Read ↗

Triple kill: DDR inhibitors, radiotherapy and immunotherapy leave cancer cells with no escapeSemantic proximity Read ↗

Molecular targets that sensitize cancer to radiation killing: From the bench to the bedsideSemantic proximity Read ↗

Advancing cancer therapy: new frontiers in targeting DNA damage responseSemantic proximity Read ↗

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancerSemantic proximity Read ↗

DNA Repair Deficiency Regulates Immunity Response in Cancers: Molecular Mechanism and Approaches for Combining ImmunotherapySemantic proximity Read ↗

Targeting DNA repair pathway in cancer: Mechanisms and clinical applicationSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Cancer Vulnerabilities Through Targeting the ATR/Chk1 and ATM/Chk2 Axes in the Context of DNA DamageSemantic proximity Read ↗

Development of PARP and Immune-Checkpoint Inhibitor CombinationsSemantic proximity Read ↗

Therapeutic Targeting of DNA Damage Response in CancerSemantic proximity Read ↗

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.